Point-of-Care Diagnostics

Never Miss
an Infection.

One device. Countless pathogens. PCR-level accuracy at near-serology costs. Built for frontline health professionals.

Discover Our Solution Contact Us

161k

Pharmacies in Europe

450K

Lyme cases / year

43%

EU pop. at risk

The Challenge

A serious Lack of
Diagnostics Solutions.

Treating an infectious disease begins with identifying it, testing for it. Yet today's frontline healthcare workers (Pharmacists, GPs , Field Services...) lack the proper tools to efficiently and rapidly diagnose most infections.
Instead, the system is simultaneously over-complicated and under-deployed, leaving vast numbers of infections undetected each year.

Gallisa addresses this structural failure by offering frontline healthcare professionals (Pharmacists, GPs, and Emergency Responders) with their own highly accurate and autonomous equipment to test on the spot and immediately deliver actionable results.

Wasted Potential

The training and talent of Pharmacists, GPs and the medical staff is lost by limiting the scope of their actions on their patient's health issues.

Uneven Access

Expensive equipment and the shortage of highly trained specialists lead to uneven access to diagnostics across countries and regions.

Chronic Under-Testing

Testing bottlenecks and prohibitive costs lead to systematic under-reporting, leaving patients untreated or treated too late.

Our Solution

One device,
countless
pathogens.

Gallisa redefines point-of-care diagnostics through an integrated hardware platform and autonomous workflows that bring testing directly to frontline healthcare professionals ( GPs, pharmacists, emergency responders...) without the need for lab infrastructures; accelerating diagnosis and enabling evidence-based clinical decisions without delay.

Universal Flexible Platform

Single device with interchangeable single-use chemical assays replacing multiple specialised instruments.

PCR-Level Accuracy

With its multi-step process, the platform delivers PCR grade results at near-serology costs.

Autonomous Process & Reporting

Standardized, autonomous workflows eliminating the need for complex operations and minimizing human error.

Test Execution

~ 20 Mins

Testing Pathway

How it works

From sample collection to diagnosis in four steps. No formal laboratory setup or training required. Thanks to the automated test platform coupled with a companion web-app, healthcare professionals and patients can run their tests with ease.

Sample Collection

The patient (or if needed, the healthcare professional) collects a sample using the consumables available in the test kit.

Sample Introduction

The patient places their sample in the proprietary cartridge and inserts it then in the testing equipment.

Automated Processing

The platform processes the sample automatically in 20 minutes then provides the user with an interpreted result.

Reporting

Thanks to the companion web-app, the patient receives a certified medical report to share with their physician.

Test Portfolio

The infections
going undetected.

Lyme Disease:
The Untested Epidemic

Lyme disease is one of Europe's most underestimated public health challenges. Around 43% of the EU population lives in tick-endemic regions, yet the disease remains severely under-reported.

When detection and treatment are delayed, the infection can disseminate across the body, leading to neurological, cardiac, and musculoskeletal complications. Early diagnosis is thus critical.

450K

Estimated actual infections (Europe)

30%

of patients are asymptomatic

3.5×

Under-reporting factor

Tick-Borne Encephalitis:
A rising health concern

Tick-borne encephalitis is a viral infection spreading across Europe with rising cases. The illness occurs in three phases: non-specific fever, then a symptom-free break, and finally neurological symptoms. This pattern causes delayed diagnosis — patients too often miss the treatable first phase.

Once neurological symptoms appear, progression is rapid and there is no specific antiviral treatment. Early detection is then critical to prevent permanent damage.

400%

Increase in # of infections

80%

of patients are asymptomatic

5×

Under-reporting factor

Toxic Shock
Syndrome

Toxic shock syndrome is a life-threatening illness caused by bacterial toxins from Staphylococcus. Although not officially reported, TSS affects all ages and demographics.

Exposure occurs through wounds or trauma, but the infection site often shows no visible signs, delaying recognition. Symptoms progress to shock within 24–48 hours. Rapid diagnosis is life-saving, as early antibiotic treatment is critical.

25%

Combined mortality rate

Max 48h

from infection to treatment

Min 2×

Under-reporting factor

Our Advantage

Why Gallisa?

Gallisa seeks to augment the capabilities of frontline healthcare workers by offering laboratory grade testing equipment tailored to be used outside of laboratories and without the supervision of a Lab technician.

Tailored for Pharmacies, GPs and Emergency Services

The Team

Meet the founders

A multidisciplinary duo committed to transforming infectious disease diagnostics from the ground up.

Jose Hajjar

Co-Founder & CEO

Trained at the intersection of engineering at EPFL and business strategy at HEC Paris, with substantial experience in the pharmaceutical industry gained at the hands of giants such as GSK, Lonza, and Merck Group.

Emma

Co-Founder & CTO

Trained in life science and IVD development at EPFL, with hands-on experience leading the end-to-end development of diagnostic assays in fast-paced start-up environments.

Let's talk.

Whether you're a healthcare professional, an investor, or simply curious, we are exited to speak with you!

Medical Professionals

Book a test session for your pharmacy or clinic.

Book a Test Session

Investors

Explore the opportunity behind next-generation diagnostics.

Reach Out

General Inquiries

Have a question or want to learn more? We'd love to hear from you.

Get in Touch

Never Miss
an Infection.